Papapetrou P D, Polymeris A
Division of Endocrinology, Alexandra Hospital, 11528 Athens, Greece.
Exp Clin Endocrinol Diabetes. 2012 Mar;120(3):164-8. doi: 10.1055/s-0032-1301897. Epub 2012 Feb 10.
Serum calcitonin (Ct) and carcinoembryonic antigen (CEA) doubling times (DT) are considered to be strong prognostic markers in patients with medullary thyroid carcinoma (MTC). The Objective of this work is to study the effect of MTC debulking on Ct and CEA DTs. 4 patients with MTC are presented who after an initial neck operation had residual disease were followed-up with serial measurements of serum Ct and CEA for several years before and after a secondary incomplete removal of involved cervical lymph nodes. The patients received no other treatment for MTC. Ct and CEA DTs were determined after fitting the Ct or CEA values to an exponential growth equation. In patient A, Ct DT increased from 1.45 years (1.17-1.89, 95% CI) preoperatively, to 5.72 (3.22-25.77) postoperatively. In patient B, Ct DT was 1.63 years (1.36-2.02) preoperatively, and very long (serum Ct practically ceased increasing) postoperatively. In patient C, Ct DT was 4.03 years (2.22-21.58) before, and very long after the operation. In patient D, Ct DT from 1.16 years (0.82-1.99) before, increased to 4.21 years (3.04-6.86) after the operation. The changes in CEA DTs were similar to those of Ct DTs in 2 patients in whom the tumor was apparently producing the protein. In conclusion, surgical MTC cytoreduction in 4 patients caused an increase in the Ct and CEA DTs, and the patients could be reclassified in new Ct DT-based strata with better prognosis than before the operation. We hypothesize that such tumor burden reduction may slow the growth of any residual MTC and we discuss mechanisms that could be responsible for this phenomenon.
血清降钙素(Ct)和癌胚抗原(CEA)倍增时间(DT)被认为是甲状腺髓样癌(MTC)患者重要的预后标志物。本研究旨在探讨MTC减瘤术对Ct和CEA DT的影响。本文报告了4例MTC患者,他们在初次颈部手术后有残留病灶,在二次不完全切除受累颈部淋巴结前后数年,连续检测血清Ct和CEA。这些患者未接受其他MTC治疗。将Ct或CEA值拟合到指数生长方程后,确定Ct和CEA DT。患者A术前Ct DT为1.45年(1.17 - 1.89,95%可信区间),术后增至5.72年(3.22 - 25.77)。患者B术前Ct DT为1.63年(1.36 - 2.02),术后很长(血清Ct几乎不再升高)。患者C术前Ct DT为4.03年(2.22 - 21.58),术后很长。患者D术前Ct DT为1.16年(0.82 - 1.99),术后增至4.21年(3.04 - 6.86)。在2例肿瘤明显产生该蛋白的患者中,CEA DT的变化与Ct DT相似。总之,4例患者行MTC细胞减灭术后,Ct和CEA DT增加,患者可根据新的基于Ct DT的分层重新分类,预后较手术前更好。我们推测,这种肿瘤负荷的降低可能会减缓任何残留MTC的生长,并讨论了可能导致这种现象的机制。